Department of In Vitro Toxicology & Dermato-Cosmetology, Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels, 1090, Belgium.
Department of Pathology, School of Veterinary Medicine & Animal Science, University of São Paulo, Av. Prof. Dr. Orlando Marques de Paiva 87, Cidade Universitária, SP, 05508-270, Brazil.
Biomark Med. 2021 Apr;15(6):437-454. doi: 10.2217/bmm-2020-0691. Epub 2021 Mar 12.
Cholestasis is a major pathological manifestation, often resulting in detrimental liver conditions, which occurs in a variety of indications collectively termed cholestatic liver diseases. The frequent asymptomatic character and complexity of cholestasis, together with the lack of a straightforward biomarker, hampers early detection and treatment of the condition. The 'omics' era, however, has resulted in a plethora of cholestatic indicators, yet a single clinically applicable biomarker for a given cholestatic disease remains missing. The criteria to fulfil as an ideal biomarker as well as the challenging molecular pathways in cholestatic liver diseases advocate for a scenario in which multiple biomarkers, originating from different domains, will be assessed concomitantly. This review gives an overview of classical clinical and novel molecular biomarkers in cholestasis, focusing on their benefits and drawbacks.
胆汁淤积是一种主要的病理表现,常导致有害的肝脏状况,发生在各种被统称为胆汁淤积性肝病的病症中。胆汁淤积症的常见无症状特征和复杂性,以及缺乏直接的生物标志物,阻碍了该病症的早期发现和治疗。然而,“组学”时代产生了大量的胆汁淤积指标,但对于特定的胆汁淤积性疾病,仍然缺乏单一的临床适用的生物标志物。作为理想生物标志物需要满足的标准,以及胆汁淤积性肝病中具有挑战性的分子途径,都表明需要同时评估来自不同领域的多个生物标志物。这篇综述概述了胆汁淤积症中的经典临床和新型分子生物标志物,重点介绍了它们的优缺点。